The INSEMA study showed that refraining from SLNB did not compromise survival in patients with early-stage, cN0 breast cancer with low-risk disease (cT1, G1-G2, HR + HER2 −) receiving breast-conserving surgery [30]. This evidence concerns the gene ERBB2 and breast carcinoma.